Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

1.1K
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
1.1K
Metallic Solids02:37

Metallic Solids

20.6K
Metallic solids such as crystals of copper, aluminum, and iron are formed by metal atoms. The structure of metallic crystals is often described as a uniform distribution of atomic nuclei within a “sea” of delocalized electrons. The atoms within such a metallic solid are held together by a unique force known as metallic bonding that gives rise to many useful and varied bulk properties.
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
20.6K
Structures of Solids02:22

Structures of Solids

17.7K
Solids in which the atoms, ions, or molecules are arranged in a definite repeating pattern are known as crystalline solids. Metals and ionic compounds typically form ordered, crystalline solids. A crystalline solid has a precise melting temperature because each atom or molecule of the same type is held in place with the same forces or energy. Amorphous solids or non-crystalline solids (or, sometimes, glasses) which lack an ordered internal structure and are randomly arranged. Substances that...
17.7K
Network Covalent Solids02:18

Network Covalent Solids

16.2K
Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds.
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
16.2K
Molecular and Ionic Solids02:54

Molecular and Ionic Solids

20.0K
Crystalline solids are divided into four types: molecular, ionic, metallic, and covalent network based on the type of constituent units and their interparticle interactions.
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
20.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

619
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
619

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Reference Range of Red Cell Distribution Width-to-Albumin Ratio in Healthy US Adults: A Cross-Sectional Study.

BioMed research international·2026
Same author

Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.

Journal for immunotherapy of cancer·2026
Same author

Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer Immunotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Association Between Red Blood Cell Distribution Width-To-Albumin Ratio and Breast, Colorectal, Lung, and Prostate Cancers.

Cancer medicine·2026
Same author

Microbiome modulation in cancer immunotherapy.

Nature medicine·2026
Same author

Revisiting the impact of common medications on immune checkpoint inhibitor efficacy.

Cancer·2026

相关实验视频

Updated: Jan 31, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K

在固体瘤中推进ICOS激动性:从INDUCE-1中吸取教训

Parham Habibzadeh1, Diwakar Davar2

  • 1Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Journal for immunotherapy of cancer
|January 29, 2026
PubMed
概括

诱导性T细胞共同刺激器 (ICOS) 显示出免疫治疗的前景,但需要精确的向. 目前ICOS激动剂的临床反应有限,表明需要组合策略和生物标志物.

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 诱导性T细胞共刺激剂 (ICOS) 是一个关键的免疫调节分子.
  • 在T细胞激活时,ICOS表达被上调,影响免疫反应.
  • ICOS与其他协同刺激途径相互作用,使其成为一个复杂的治疗点.

研究的目的:

  • 在I期研究中评估ICOS激动剂费拉迪利马布的安全性和生物活性.
  • 探索ICOS激动症在癌症免疫治疗中的治疗潜力.
  • 了解限制ICOS激动剂临床疗效的因素.

主要方法:

  • 第I阶段INDUCE-1研究采用药理动力学指导设计.
  • 用费拉迪利马布 (GSK3359609) 来评估安全性和受体占用.
  • 与之前的ICOS激动剂研究进行比较,例如vopratelimab (JTX-2011).

主要成果:

  • 费拉迪利马布证明了良好的安全性,并实现了强大的受体占用率.
  • 对费拉迪利马布的临床反应有限,类似于其他ICOS激动剂.
  • 有效的ICOS调制需要仔细考虑T细胞反应和通路相互作用.
关键词:
免疫检查点抑制剂 免疫检查点抑制剂作为共同抑制分子的分子.具有共同刺激性的分子.

更多相关视频

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

3.3K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.3K

相关实验视频

Last Updated: Jan 31, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

3.3K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.3K

结论:

  • ICOS激动症显示出潜力,但在实现显著的临床疗效方面面临挑战.
  • 未来的策略需要结合疗法和基于生物标志物的患者选择ICOS向治疗.
  • 优化ICOS调节需要了解免疫细胞群的空间和时间调节.